Paid Clinical Trials Laramie
Discover 37 paid clinical trials in Laramie, Wyoming. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder CancerTesting the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04164082
Conditions
Bladder Flat Urothelial Carcinoma In Situ
Non-Muscle Invasive Bladder Urothelial Carcinoma
Stage 0a Bladder Cancer AJCC v8
Stage 0is Bladder Cancer AJCC v8
Stage I Bladder Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biopsy
Biospecimen Collection
Computed Tomography
Cystoscopy
Gemcitabine Hydrochloride
MILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims StudyMILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims Study
Sponsor:
Vertos Medical, Inc.
Location:
Code:
NCT03072927
Conditions
Lumbar Spinal Stenosis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
MILD
Interspinous Process Decompression
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerOsimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04181060
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Stage IIIB Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bevacizumab
Biospecimen Collection
Computed Tomography
Echocardiography
Magnetic Resonance Imaging
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT02201992
Conditions
ALK Gene Rearrangement
ALK Gene Translocation
ALK Positive
Stage IB Non-Small Cell Lung Carcinoma AJCC v7
Stage II Non-Small Cell Lung Cancer AJCC v7
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Clinical Observation
Crizotinib
Laboratory Biomarker Analysis
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST TrialTesting the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04267848
Conditions
Lung Non-Small Cell Carcinoma
Lung Non-Small Cell Squamous Carcinoma
Lung Non-Squamous Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Carboplatin
Cisplatin
Computed Tomography
Echocardiography
Evaluation of Body Composition Improvement With Visceral Adiposity-Focused Anti-Obesity Telehealth ProgramEvaluation of Body Composition Improvement With Visceral Adiposity-Focused Anti-Obesity Telehealth Program
Sponsor:
20Lighter
Location:
Code:
NCT05219240
Conditions
Obesity
Cardiovascular Diseases
Metabolic Syndrome
Metabolic Disease
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
20Lighter Program
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering MyelomaLenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT03937635
Conditions
Smoldering Plasma Cell Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Daratumumab
Dexamethasone
Lenalidomide
Quality-of-Life Assessment
Questionnaire Administration
Intravesical BCG vs GEMDOCE in NMIBCIntravesical BCG vs GEMDOCE in NMIBC
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT05538663
Conditions
Non-muscle-invasive Bladder Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Gemcitabine
Docetaxel
Bacillus Calmette Guerin
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
Sponsor:
Amneal Pharmaceuticals, LLC
Location:
Code:
NCT05401357
Conditions
Glaucoma, Open-Angle
Ocular Hypertension
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Test - Bimatoprost 0.01% Ophthalmic Solution
Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy DurationS1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT04071457
Conditions
Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Lenalidomide
Daratumumab/rHuPH20